The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Successfully managing weight after a course of the popular fat jabs does not end with the completion of the medication, ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Doctors at ZAVA warned that these summer staples can cause your blood sugar levels to crash and dehydrate you. This effect ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

I have been diagnosed with mild sleep apnea. (No surprise there as symptoms were omnipresent.) CPAP machines seem incredibly uncomfortable. Are they the preferred gold standard even for mild sleep ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...